ACOX3

Across TCGA pan-cancer cohorts, ACOX3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ACOX3 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ACOX3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACOX3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and OV are the cancer types where ACOX3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.137	0.722	<.001	33	view →
UCEC	DFS	Median	All	0.976	0.827	.011	26	view →
OV	OS	Median	II,III,IV	0.289	0.692	.020	18	view →
COAD	OS	Median	IV	0.045	0.659	<.001	12	view →
CESC	DFS	Median	III,IV	0.240	0.726	.015	6	view →
BLCA	OS	Median	III,IV	0.090	0.582	<.001	6	view →
STAD	OS	Median	III,IV	0.501	0.629	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ACOX3–LUSC (DFS)

Open the LUSC breakdown →